Renalytix Plc (RENX.L)
| Previous close | 13.50 |
| Open | 13.65 |
| Bid | 13.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 13.10 - 13.70 |
| 52-week range | 10.00 - 125.00 |
| Volume | |
| Avg. volume | 482,029 |
| Market cap | 22.4M |
| Beta (5Y monthly) | 2.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | 26 Sept 2024 - 30 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.87 |
GlobeNewswireRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno’), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease (DKD). The initial focus
- PR Newswire
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
Globe NewswireRenalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearing
